Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2015
At a glance
- Drugs Alprazolam (Primary)
- Indications Anxiety disorders
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Mar 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
- 19 Aug 2010 Planned initiation date changed from 1 Sep 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 19 Aug 2010 Planned end date changed from 1 Oct 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.